Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent

Blood

Volumn 117, Issue 18, 2011, Pages 4964-4967

  Gersh, Kathryn C ^a   Zaitsev, Sergei ^a   Cines, Douglas B ^a   Muzykantov, Vladimir ^a   Weisel, John W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; UROKINASE;

ARTERY BLOOD FLOW; ARTICLE; BLOOD CLOT; BLOOD CLOT LYSIS; CHANNEL GATING; ERYTHROCYTE; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHEAR STRESS; VEIN BLOOD FLOW;

EID: 79955951798     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-310409     Document Type: Article

References (14)

1. Selim M. Perioperative stroke. N Engl J Med. 2007;356(7):706-713.
2. Zlokovic BV. Antithrombotic, procoagulant, and fibrinolytic mechanisms in cerebral circulation: implications for brain injury and protection. Neurosurg Focus. 1997;2:e5.
3. Collen D. Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation. 1996; 93(5):857-865. (Pubitemid 26074821)
4. Holvoet P, Dewerchin M, Stassen JM, et al. Thrombolytic profiles of clot-targeted plasminogen activators: parameters determining potency and initial and maximal rates. Circulation. 1993; 87(3):1007-1016. (Pubitemid 23070832)
5. Murciano JC, Medinilla S, Eslin D, Atochina E, Cines DB, Muzykantov VR. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol. 2003;21(8):891-896. (Pubitemid 36936194)
6. Danielyan K, Ganguly K, Ding BS, et al. Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation. 2008;118(14):1442-1449.
7. Stein SC, Ganguly K, Belfield CM, et al. Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury. J Neurotrauma. 2009;26(9):1585-1592.
8. Zaitsev S, Spitzer D, Murciano JC, et al. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood. 2010;115(25):5241-5248.
9. Zaitsev S, Spitzer D, Murciano JC, et al. Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J Pharmacol Exp Ther. 2010;332(3):1022-1031.
10. Muzykantov VR. Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv. 2010;7(4):403-427.
11. Gersh KC, Zaitsev S, Muzykantov V, Cines DB, Weisel JW. The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics. J Thromb Haemost. 2010;8(5):1066-1074.
12. Sakharov DV, Rijken DC. The effect of flow on lysis of plasma clots in a plasma environment. Thromb Haemost. 2000;83(3):469-474. (Pubitemid 30148363)
13. Blinc A, Keber D, Lahajnar G, Stegnar M, Zidansek A, Demsar F. Lysing patterns of retracted blood clots with diffusion or bulk flow transport of plasma with urokinase into clots: a magnetic resonance imaging study in vitro. Thromb Haemost. 1992;68(6):667-671.
14. Blinc A, Kennedy SD, Bryant RG, Marder VJ, Francis CW. Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost. 1994;71(2):230-235. (Pubitemid 24047333)